The company announced in a press release that its SB-525 developed with Pfizer was "generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,